Combitube

Combitube is a type of airway management device that is used in emergency situations when endotracheal intubation is not possible. It is a dual-lumen tube that can be inserted blindly into the esophagus or the trachea, providing a clear airway for ventilation.

History

The Combitube was first introduced in the 1980s by Dr. Franz Frass, a professor of anesthesiology at the University of Vienna. It was designed as an alternative to traditional endotracheal intubation, which requires a high level of skill and can be difficult to perform in emergency situations.

Design

The Combitube consists of two tubes, or lumens, that are connected at the distal end. One lumen is designed to be inserted into the esophagus, while the other is designed to be inserted into the trachea. Both lumens have inflatable cuffs that can be inflated to seal off the esophagus and trachea, preventing aspiration of stomach contents and ensuring that air is directed into the lungs.

Use

The Combitube is typically used in emergency situations when endotracheal intubation is not possible or has failed. It can be inserted blindly, without the need for a laryngoscope, and does not require visualization of the vocal cords. This makes it a useful tool in situations where the patient's airway is difficult to visualize or access, such as in cases of facial trauma or severe edema.

Advantages and Disadvantages

The main advantage of the Combitube is its ease of use. It can be inserted quickly and without the need for specialized equipment or training. However, it does have some disadvantages. The Combitube does not provide as secure an airway as endotracheal intubation, and there is a risk of esophageal injury if the tube is inserted incorrectly. In addition, the Combitube cannot be used in children or in adults with a small esophagus.

See Also

• Airway management
• Endotracheal intubation
• Esophagus
• Trachea

Combitube Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.